FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247258364> ?p ?o ?g. }

• W2247258364 abstract "11049 Background: We have previously reported (ASCO 2006) the efficacy and toxicity of 4 courses of M (75mg/m 2 ) and T (75mg/m 2 ) with G-CSF support in a 21 day schedule as neoadjuvant treatment in patients with resectable breast cancer. Aim: To evaluate the clinical and pathological response rate (RR) and toxicity of biweekly M and T given prior to surgery in patients with breast cancer. Methods: Patients with histological confirmation of breast cancer (stage II-III and inflammatory), age >18 years, left ventricular ejection fraction > 45% and adequate bone marrow, renal and hepatic function were included in the study. Prior systemic therapy, radiotherapy or surgery for breast cancer were not allowed. The treatment was: M (60 mg/m 2 ) and T (60mg/m 2 ) each in 1 hour infusion, with subcutaneous G-CSF (5 mcg/kg) support on days 4–9. Courses were repeated every 14 days. Patients received 6 courses prior to surgery. Results: To date 45 patients have been enrolled; 20 who have completed therapy and underwent surgery (except for patients with progression) were included in this interim analysis. Median age: 48 years (38–63), ECOG PS 0: 90%, ECOG PS1: 10%, postmenopausal: 35%. Histology was infiltrating ductal carcinoma in 80%. Patients received a total of 110 courses (median 6, range 2–6). Efficacy: Of 19 evaluable patients, 4 achieved a clinical complete response (cCR) (21%), 12 partial response (cPR) (63%), 1 stable disease (cSD) (5%) and 2 progressive disease (cPD) (10%), resulting in a clinical response rate (cRR) of 84%. Surgery was performed in 17 (85%) patients, 4 (23%) of them had pathological complete response (pCR), 12 (70%) partial response (pPR), 1 (6%) stable disease (pSD), resulting in a pathological RR of 93%. Median time to progression and overall survival have not been reached. Toxicity: Hematological grade III/IV toxicities per patient were neutropenia (10%), febrile neutropenia (10%) and thrombocytopenia (5%). Non-hematological grade III/IV toxicities per patient were mucositis (10%), nausea/vomiting (10%) and epigastralgia (10%) Conclusions: Six courses of T and M every 14 days with G- CSF support as induction treatment in stage II and III breast cancer are active and well tolerated. No significant financial relationships to disclose." @default.
• W2247258364 created "2016-06-24" @default.
• W2247258364 creator A5007616426 @default.
• W2247258364 creator A5019667620 @default.
• W2247258364 creator A5022387941 @default.
• W2247258364 creator A5040176117 @default.
• W2247258364 creator A5043967749 @default.
• W2247258364 creator A5050984986 @default.
• W2247258364 creator A5052205300 @default.
• W2247258364 creator A5060343163 @default.
• W2247258364 creator A5061487896 @default.
• W2247258364 creator A5077505675 @default.
• W2247258364 date "2007-06-20" @default.
• W2247258364 modified "2023-09-26" @default.
• W2247258364 title "Biweekly nonpegylated liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II-III breast cancer" @default.
• W2247258364 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.11049" @default.
• W2247258364 hasPublicationYear "2007" @default.
• W2247258364 type Work @default.
• W2247258364 sameAs 2247258364 @default.
• W2247258364 citedByCount "3" @default.
• W2247258364 crossrefType "journal-article" @default.
• W2247258364 hasAuthorship W2247258364A5007616426 @default.
• W2247258364 hasAuthorship W2247258364A5019667620 @default.
• W2247258364 hasAuthorship W2247258364A5022387941 @default.
• W2247258364 hasAuthorship W2247258364A5040176117 @default.
• W2247258364 hasAuthorship W2247258364A5043967749 @default.
• W2247258364 hasAuthorship W2247258364A5050984986 @default.
• W2247258364 hasAuthorship W2247258364A5052205300 @default.
• W2247258364 hasAuthorship W2247258364A5060343163 @default.
• W2247258364 hasAuthorship W2247258364A5061487896 @default.
• W2247258364 hasAuthorship W2247258364A5077505675 @default.
• W2247258364 hasConcept C121608353 @default.
• W2247258364 hasConcept C126322002 @default.
• W2247258364 hasConcept C126894567 @default.
• W2247258364 hasConcept C141071460 @default.
• W2247258364 hasConcept C2781190966 @default.
• W2247258364 hasConcept C509974204 @default.
• W2247258364 hasConcept C530470458 @default.
• W2247258364 hasConcept C71924100 @default.
• W2247258364 hasConceptScore W2247258364C121608353 @default.
• W2247258364 hasConceptScore W2247258364C126322002 @default.
• W2247258364 hasConceptScore W2247258364C126894567 @default.
• W2247258364 hasConceptScore W2247258364C141071460 @default.
• W2247258364 hasConceptScore W2247258364C2781190966 @default.
• W2247258364 hasConceptScore W2247258364C509974204 @default.
• W2247258364 hasConceptScore W2247258364C530470458 @default.
• W2247258364 hasConceptScore W2247258364C71924100 @default.
• W2247258364 hasLocation W22472583641 @default.
• W2247258364 hasOpenAccess W2247258364 @default.
• W2247258364 hasPrimaryLocation W22472583641 @default.
• W2247258364 hasRelatedWork W113810927 @default.
• W2247258364 hasRelatedWork W1586374228 @default.
• W2247258364 hasRelatedWork W2003938723 @default.
• W2247258364 hasRelatedWork W2047967234 @default.
• W2247258364 hasRelatedWork W2118496982 @default.
• W2247258364 hasRelatedWork W2364998975 @default.
• W2247258364 hasRelatedWork W2369162477 @default.
• W2247258364 hasRelatedWork W2439875401 @default.
• W2247258364 hasRelatedWork W4238867864 @default.
• W2247258364 hasRelatedWork W2525756941 @default.
• W2247258364 isParatext "false" @default.
• W2247258364 isRetracted "false" @default.
• W2247258364 magId "2247258364" @default.
• W2247258364 workType "article" @default.